{
  "emaEpar": [],
  "fdaDrugLabel": [],
  "id": "Farletuzumab",
  "nciThesaurus": {
    "casRegistry": "896723-44-7",
    "chebiId": "",
    "chemicalFormula": "",
    "definition": "A humanized, immunoglobulin G1 monoclonal antibody with potential antitumor activity. Farletuzumab specifically targets at glycoprotein 3 (GP-3), a cell surface antigen that is overexpressed on many epithelial-derived cancer cells. Upon binding to the GP-3 antigen, farletuzumab triggers a host immune response against GP-3 expressing cells resulting in cell lysis.",
    "fdaUniiCode": "2O09BG0OWA",
    "identifier": "C61503",
    "preferredName": "Farletuzumab",
    "semanticType": "Amino Acid, Peptide, or Protein",
    "subclassOf": [
      "C20401"
    ],
    "synonyms": [
      "FARLETUZUMAB",
      "Farletuzumab",
      "MORAb-003"
    ]
  }
}